表皮调节素与肿瘤的相关性研究进展

梅 丽(内蒙古医科大学，中国)
群 呼(内蒙古医科大学附属医院，中国)

摘要

人类表皮调节素（EREG）是表皮生长因子受体（Epidermal Growth Factor Receptor，EGFR）的配体，属于EGF家族之一。EGF家族包括表皮调节素（Epiregulin，EREG）、肿瘤生长因子-α（TGF-α）、表皮生长因子（Epidermal Growth Factor，EGF）、肝素结合性EGF样生长因子（HB-EGF）、β细胞素（Betacellulin，BTC）、AREG、上皮细胞有丝分裂原（epigen，EPGN）和神经调节素（Neuregulin，NRG）共8个成员。其中表皮调节素在肿瘤的发生、发展、侵袭和迁移等方面有极其重要的调控作用。近年来，多项研究结果表明EREG的表达水平可能与肿瘤患者的预后及药物疗效预测相关。深入了解表皮调解素，可对攻克癌症的研究带来新的突破和进展。论文就ERER的结构、功能以及在人类各类肿瘤的发生发展中的研究做一综述。

关键词

表皮调节素；表皮生长因子受体；肿瘤

参考

Toyoda H, Komurasaki T, Uchida D, et al. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes[J]. The Journal of biological chemistry, 1995(13):270.

Sahin U. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands[J]. Journal of Cell Biology, 2004,164(5):769-779.

Komurasaki T, Toyoda H, Uchida D, et al. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4[J]. Oncogene, 1997,15(23):2841-2848.

Sunaga N, Kaira K, Imai H, et al. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer[J]. Oncogene, 2013,32(34):4034-4042.

Sangjun Lee, Dan Medina, Anna Tsimelzon, et al. Craig Allred.Alterations of Gene Expression in the Development of Early Hyperplastic Precursors of Breast Cancer[J]. American Journal Of Pathology, 2007,171(1):252-262.

Mariya, Farooqui, Laura, et al. Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival[J]. Molecular Cancer, 2015.

Li T, Feng R, Chen B, et al. EREG is a risk factor for the prognosis of patients with cervical cancer[J]. Front Med (Lausanne), 2023,20(10):1161835.

Zhou Y, Xiao D, Jiang X, et al. EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma[J]. Journal of Translational Medicine, 2023,21(1):1-25.

DOI: http://dx.doi.org/10.26549/nrr.v3i1.16698